HALAL STUDIES AND PREDICTION OF DELTA9 TETRAHYDROCANNABINOLIC ACID FROM GANJA LEAF (CANABIS SATIVA) AS ACUTE NEUROLOGIC DISORDERS TREATMENT

Yuneka  Saristiana; Novynanda  Salmasfattah; Fendy Prasetyawan; Muhammad Nurul Fadel; Emma Jayanti  Besan; Ratna Mildawati; Abd Rofiq; Widhi Astutik; Chandra Arifin; M Wahyu Ariawan; Ilhawa Zahra; Rika Amelia

Authors

Yuneka Saristiana Universitas Kadiri Author
Novynanda Salmasfattah Universitas Kadiri Author
Fendy Prasetyawan Universitas Kadiri Author
Muhammad Nurul Fadel Universitas Muhammadiyah Kudus Author
Emma Jayanti Besan Universitas Muhammadiyah Kudus Author
Ratna Mildawati STIKes Ganesha Husada Kediri Author
Abd Rofiq Akademi Kesehatan Arga Husada Author
Widhi Astutik Institut Ilmu Kesehatan Bhakti Wiyata Author
Chandra Arifin Akademi Kesehatan Arga Husada Author
M Wahyu Ariawan Universitas Tulang Bawang Author
Ilhawa Zahra Universitas Sari Mutiara Indonesia Author
Rika Amelia Universitas Sari Mutiara Indonesia Author

Keywords:

Delta9-Tetrahydrocannabinolic Acid, acute neurologic disorders, PASS prediction, Halal

Abstract

Delta9-Tetrahydrocannabinolic Acid (Δ9-THCA), a non-psychoactive precursor of tetrahydrocannabinol (THC), has been computationally predicted as a potential treatment for acute neurologic disorders. Using the Way2Drug PASS (Prediction of Activity Spectra for Substances) tool, the analysis yielded a Probability of Activity (Pa) value of 0.769, indicating a high likelihood of Δ9-THCA’s therapeutic potential. The Probability of Inactivity (Pi) value of 0.011 suggests a very low chance of inefficacy, supporting its pharmacological relevance in treating neurological conditions. Δ9-THCA is known for its anti-inflammatory, neuroprotective, and anti-excitotoxic properties, which are essential in managing stroke, traumatic brain injury, epilepsy, and neurodegenerative diseases. Its interaction with the endocannabinoid system (ECS), particularly CB1 and CB2 receptors, may contribute to neuroprotection by modulating neurotransmitter release, reducing oxidative stress, and preventing excitotoxicity. These mechanisms align with previous studies on cannabinoids, further strengthening the computational prediction. Despite these promising findings, further in-vitro and in-vivo investigations are required to confirm Δ9-THCA’s efficacy, pharmacokinetics, and safety profile.

Keywords: Delta9-Tetrahydrocannabinolic Acid, acute neurologic disorders, PASS prediction

References

Ardianto, N., Prasetyawan, F., Saristiana, Y., Muslikh, F. A., Mildawati, R., & Dhafin, A. A. & Rofiq, A. (2023). Forensic Pharmacy Case Study: Identification of Hazardous Mercury Content as a Whitening Agent in Beauty Cream Products. International Journal of Contemporary Sciences (IJCS), 1(2), 85-90.

Atakan, Z. (2012). Cannabis, a complex plant: Different compounds and different effects on individuals. Therapeutic Advances in Psychopharmacology, 2(6), 241-254. https://doi.org/10.1177/2045125312457586

Basavarajappa, B. S., Nixon, R. A., & Arancio, O. (2017). Endocannabinoid system: Emerging role from neurodevelopment to neurodegeneration. Mini-Reviews in Medicinal Chemistry, 17(3), 222-236. https://doi.org/10.2174/1389557516666160921110537

Bhattacharyya, S., Morrison, P. D., Fusar-Poli, P., Martin-Santos, R., Borgwardt, S., Winton-Brown, T., & Seal, M. (2010). Opposite effects of Δ-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology, 35(3), 764-774. https://doi.org/10.1038/npp.2009.184

Blair, R. E., Deshpande, L. S., Sombati, S., Elphick, M. R., Matagne, A., & DeLorenzo, R. J. (2009). Prolonged phytocannabinoid treatment of hippocampal neuronal cultures and in vivo seizure models results in anticonvulsant tolerance. Neuropharmacology, 57(8), 841-846. https://doi.org/10.1016/j.neuropharm.2009.08.002

Boggs, D. L., Nguyen, J. D., Morgenson, D., Taffe, M. A., & Ranganathan, M. (2018). Clinical and preclinical evidence for functional interactions of cannabidiol and Δ9-tetrahydrocannabinol. Neuropsychopharmacology, 43(1), 142-154. https://doi.org/10.1038/npp.2017.209

Devinsky, O., Cilio, M. R., Cross, H., Fernandez‐Ruiz, J., French, J., Hill, C., ... & Friedman, D. (2014). Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia, 55(6), 791-802. https://doi.org/10.1111/epi.12631

Di Marzo, V. (2008). Targeting the endocannabinoid system: To enhance or reduce? Nature Reviews Drug Discovery, 7(5), 438-455. https://doi.org/10.1038/nrd2553

Fisar, Z. (2009). Phytocannabinoids and endocannabinoid system. Current Drug Abuse Reviews, 2(1), 51-75. https://doi.org/10.2174/1874473700902010051

Grotenhermen, F., & Müller-Vahl, K. (2012). The therapeutic potential of cannabis and cannabinoids. Dtsch Arztebl Int, 109(29-30), 495-501. https://doi.org/10.3238/arztebl.2012.0495

Iuvone, T., Esposito, G., De Filippis, D., Scuderi, C., & Steardo, L. (2009). Cannabinoids and neuroprotection. Molecular Neurobiology, 40(1), 65-72. https://doi.org/10.1007/s12035-009-8073-7

Koppel, B. S., Brust, J. C., Fife, T., Bronstein, J., Youssof, S., Gronseth, G., & Gloss, D. (2014). Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders. Neurology, 82(17), 1556-1563. https://doi.org/10.1212/WNL.0000000000000363

Mayasari, S., Maulita, S. N., Soleh, A. A. P. M., Prasetyawan, F., & Ningsih, A. W. (2025). Formulation And Physical Properties Testing Of Lip Tint Preparations Of Akalifa Leaf Extract (Acalypha Wilkeisiana Mueill. Arg). Jurnal EduHealth, 16(01), 155-165.

Mildawati, R., Kristijono, A., Prasetyawan, F., Saristiana, Y., & Nugroho, B. P. (2024). Sosialisasi Penyakit Populer Dikalangan Muda-Mudi Melalui Penerapan Pola Hidup Sehat. Jurnal Pengabdian Kepada Masyarakat Al-Amin, 2(1), 11-17.

Morales, P., Hurst, D. P., Reggio, P. H. (2017). Molecular targets of the phytocannabinoids: A complex picture. Progress in the Chemistry of Organic Natural Products, 103, 103-131. https://doi.org/10.1007/978-3-319-45541-9_4

Muslikh, F. A., Prasetyawan, F., Hesturini, R. J., Sari, F., & Mawarni, O. K. (2023). Physicochemical and Pharmacokinetic Property Prediction of Substances in Centella asiatica using pkCSM: Prospects for the Creation of Therapeutic Formulations from Plant Isolates. International Journal of Global Sustainable Research, 1(3), 485-494.

Nugroho, B. P., Mildawati, R., Prasetyawan, F., Saristiana, Y., & Oktadiana, I. (2024). Sosialisasi Obat Herbal Dan Edukasi Pemilihan Obat Herbal. Abdi Masyarakat Vokasi, 1(1), 96-101.

Oktadiana, I., Daulay, M., Mildawati, R., Prasetyawan, F., Saristiana, Y., & Nugroho, B. P. (2024). Penyuluhan Dan Sosialisasi Tanaman Obat Keluarga Untuk Menurunkan Kadar Gula Darah Di Desa Batu Dua Kabupaten Simalungun. Abdi Masyarakat Vokasi, 1(1), 73-79.

Pertwee, R. G. (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol, and Δ9-tetrahydrocannabivarin. British Journal of Pharmacology, 153(2), 199-215. https://doi.org/10.1038/sj.bjp.0707442

Prasetyawan, F., Karingga, D. D. K., Saristiana, Y., Mildawati, R., & Astutik, W. (2024). Edukasi Menjaga Pola Hidup Sehat Tentang Penyakit Diabetes Melitus dan Hipertensi Pada Era COVID-19 Di Car Free Day Kota Kediri. Interaksi: Jurnal Pengabdian Kepada Masyarakat, 1(1), 13-19.

Russo, E. B. (2011). Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology, 163(7), 1344-1364. https://doi.org/10.1111/j.1476-5381.2011.01238.x

Saristiana, Y., Setyarini, A. D., Permatasari, Y. D., Susilowati, A. A., & Prasetyawan, F. (2024). Exploring the Macroscopic and Microscopic Characteristics of Acalypha indica L. Simplisia Powder in the Context of Pharmabotanical Studies. International Journal of Contemporary Sciences (IJCS), 1(3), 31-42.

Turner, S. E., Williams, C. M., Iversen, L., & Whalley, B. J. (2017). Molecular pharmacology of phytocannabinoids. Progress in the Chemistry of Organic Natural Products, 103, 61-101. https://doi.org/10.1007/978-3-319-45541-9_3